Table 4. Evolution of CTC counts for 75 patients who had undergone follow-up CTC evaluation under treatment 1–2 months after baseline CTC evaluation according to immunohistochemical subtype.
| Subgroup | All patients | Patients with <5 CTC baseline and at FU | Patients with ⩾5 CTC baseline and <5 CTC at FU | Patients with ⩾5 CTC at FU |
|---|---|---|---|---|
| Luminal A |
27 |
10 (37%) |
5 (19%) |
12 (44%) |
| Luminal B–HER2-negative |
12 |
6 (50%) |
3 (25%) |
3 (25%) |
| Luminal B–HER2-positive |
20 |
7 (35%) |
12 (60%) |
1 (5%) |
| HER2-positive (non-luminal) |
9 |
3 (33%) |
6 (67%) |
0 (0%) |
| Triple negative |
5 |
2 (40%) |
2 (40%) |
1 (20%) |
| Unclassified (missing data) |
2 |
— |
— |
— |
| P=0.018 | ||||
Abbreviations: CTC=circulating tumour cells; FU=follow-up. Bold value indicates significant P-value (P<0.05).